Germany RUO Immunoassay market is set to witness a CAGR of 12.17% from 2025 to 2030.
Germany's RUO Immunoassay market is expanding due to several factors. One of the primary reasons is the research for potential biomarkers of disease, used to screen large numbers of samples. Favorable investments are accelerating the market growth. Some recent examples are listed below:
The European Investment Bank (EIB) has signed a quasi-equity financing agreement of up to €20 million with Numares Health AG for their innovative solutions. The company will analyze biomarkers with advanced nuclear magnetic resonance and artificial intelligence to improve diagnostics. The company will use research and development to improve diagnostic quality for chronic kidney, heart, and liver diseases, as well as cancer and multiple sclerosis,
Similarly, DFG, the German Research Foundation will fund seven new Research Units, one new Clinical Research Unit, and new Research Units will receive a total funding of approximately €40 million. Currently, the DFG is providing funding for a total of 185 Research Units, along with 13 Clinical Research Units and 18 Centers for Advanced Studies in Humanities and Social Sciences. Aligned with this, Medipan GmbH based in Germany, is funded by the European Union and the State of Brandenburg. The company operates in radioimmunoassay products for the characterization of thyroid function, disease, and tumor markers, with its partners from nuclear medicine laboratories.
Moreover, Cipla (EU) Limited, acquired a 10.35% stake in Ethris GmbH, in 2023 in Germany, a pre-clinical stage firm working on a mRNA platform. This will provide Cipla access to its mRNA platform and the mRNA-based products developed by Ethris.
Germany is one of the promising markets for medicinal and pharma products, in 2022, Germany was the largest EU exporter with a revenue of €68 billion, followed by Belgium €56 billion, and Ireland €42 billion. Pharmaceutical products were the main commodities traded in 2022, with 7.5% of the total trade of the country.
The companies based in Germany, such as Euroimmun, received the required certificate for their quality management system following the new European Regulation on in vitro diagnostic medical devices (IVDR), in August 2023.
Further, in July 2022, IDS launched IVDR Complaint Class A Products, for healthcare professionals. They also added 4 new assays Ultra-Sensitive AMH/MIS ELISA, picoAMH ELISA, Inhibin A ELISA, and Ultra-Sensitive Inhibin B ELISA, in May 2022.
Along with that, Siemens Healthineers AG listed in Germany, launched Atellica CI Analyzer, a compact testing system, that integrates immunoassay and clinical chemistry testing to alleviate labor shortage challenges and boost revenue growth, promoting flexibility and comparability. These developments open up opportunities catering to the growing need for ROU immunoassay solutions offered by German companies.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Growth Rate | CAGR of 12.17% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | North Rhine-Westphalia, Bavaria, Baden Wurttemberg, Hesse, Lower Saxony |
| List of Major Companies in the Germany RUO Immunoassay Market | |
| Customization Scope | Free report customization with purchase |
Germany RUO Immunoassay Market Segmentation
By Product Type
By Sample Type
By Application
By End-User
By State